ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Pilot Study Exploring the Effect of Its Oral T Therapy, KYZATREX®on Male Fertility
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 273572" data-attributes="member: 13851"><p>RALEIGH, N.C., Jan. 9, 2024 /PRNewswire/ --<em> <a href="https://c212.net/c/link/?t=0&l=en&o=4062862-1&h=260183814&u=http%3A%2F%2Fwww.mariuspharma.com%2F&a=Marius+Pharmaceuticals" target="_blank">Marius Pharmaceuticals</a>, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announced it has <strong>initiated a pilot study to better understand the effect of oral testosterone replacement therapy, KYZATREX® (testosterone undecanoate), on spermatogenesis in adult males. </strong>KYZATREX is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.</em></p><p><em></em></p><p><em><strong>While it is generally accepted that TRT in males decreases spermatogenesis, which occurs through suppression of the hypothalamic-pituitary-gonadal axis, most data are derived from traditional routes of administration of TRT (e.g., injections, patches, gels, implantable pellets, etc.). <u>This study will be the first of its kind to specifically examine the effects of an oral TRT, like KYZATREX, on spermatogenesis</u>. </strong>Importantly, the American Urological Association currently <a href="https://c212.net/c/link/?t=0&l=en&o=4062862-1&h=1806729242&u=https%3A%2F%2Fwww.auanet.org%2Fguidelines-and-quality%2Fguidelines%2Ftestosterone-deficiency-guideline&a=recommends" target="_blank">recommends</a> that physicians prescribing TRT inform their patients of the risks of the therapy on fertility.</em></p><p><em></em></p><p><em><strong>"We are eager to begin this new pilot study, as finding an option of TRT that does not reduce fertility in men would be a significant milestone in the field of andrology and society as a whole," </strong>said Andrew Sun, M.D., Director at the Center for Men's Health at Urology Partners of North Texas and Chief Medical Advisor for Marius Pharmaceuticals. <strong>"Too many men are suffering in silence from the effects of testosterone deficiency, and the results from this study could help us better understand the effects of oral TRT on spermatogenesis, which might potentially benefit a subset of men; those who are looking to start a family while still treating their low T."</strong></em></p><p><em><strong></strong></em></p><p><em><strong>Led by principal investigator <a href="https://c212.net/c/link/?t=0&l=en&o=4062862-1&h=510963481&u=https%3A%2F%2Fwww.bcm.edu%2Fpeople-search%2Fmohit-khera-24469&a=Dr.+Mohit+Khera" target="_blank">Dr. Mohit Khera</a>, Director of the Laboratory for Andrology Research Baylor College of Medicine, the study will enroll 20 male patients, ages 18-49 years old, who meet the American Urological Association's <a href="https://c212.net/c/link/?t=0&l=en&o=4062862-1&h=1433572264&u=https%3A%2F%2Fwww.auanet.org%2Fguidelines-and-quality%2Fguidelines%2Ftestosterone-deficiency-guideline&a=criteria" target="_blank">criteria</a> for hypogonadism and who have not previously used TRT. </strong>"Historically, testosterone products have been known to impair sperm production. Thus, many young hypogonadal men planning to achieve a pregnancy are unable to use testosterone due to an increased risk of suppressing their sperm production," said Dr. Khera. <strong>"Identifying testosterone therapy that could potentially not suppress sperm production would be a significant advancement in the way we treat these hypogonadal men."</strong></em></p><p></p><p><strong><em>Participating patients will receive 200-400mg of KYZATREX BID for three months. <u>Two semen analyses will be performed at baseline, one month, and three months, to assess any changes in each patient's sperm count</u>. <u>Blood draws will also be taken at each of these time points to measure testosterone, hormones, lipids, and hematocrit</u>. <u>There will also be an additional blood draw two weeks after starting the therapy to support drug titration to reach therapeutic levels</u>. <u>Additionally, patients will receive the IIEF, PHQ-9, and SF36 questionnaires at baseline and at the conclusion of the study to assess symptoms of low testosterone</u>.</em></strong></p><p></p><p><em><strong>This pilot study is part of Marius Pharmaceuticals' comprehensive effort to develop innovative therapies for testosterone deficiency.</strong> To learn more about KYZATREX, visit <a href="https://c212.net/c/link/?t=0&l=en&o=4062862-1&h=2765236701&u=https%3A%2F%2Fwww.kyzatrex.com%2F&a=https%3A%2F%2Fwww.kyzatrex.com" target="_blank">https://www.kyzatrex.com</a>. To learn more about Marius Pharmaceuticals, visit <a href="https://c212.net/c/link/?t=0&l=en&o=4062862-1&h=785214352&u=https%3A%2F%2Fwww.mariuspharma.com%2F&a=https%3A%2F%2Fwww.mariuspharma.com" target="_blank">https://www.mariuspharma.com</a>.</em></p></blockquote><p></p>
[QUOTE="madman, post: 273572, member: 13851"] RALEIGH, N.C., Jan. 9, 2024 /PRNewswire/ --[I] [URL='https://c212.net/c/link/?t=0&l=en&o=4062862-1&h=260183814&u=http%3A%2F%2Fwww.mariuspharma.com%2F&a=Marius+Pharmaceuticals']Marius Pharmaceuticals[/URL], a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announced it has [B]initiated a pilot study to better understand the effect of oral testosterone replacement therapy, KYZATREX® (testosterone undecanoate), on spermatogenesis in adult males. [/B]KYZATREX is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. [B]While it is generally accepted that TRT in males decreases spermatogenesis, which occurs through suppression of the hypothalamic-pituitary-gonadal axis, most data are derived from traditional routes of administration of TRT (e.g., injections, patches, gels, implantable pellets, etc.). [U]This study will be the first of its kind to specifically examine the effects of an oral TRT, like KYZATREX, on spermatogenesis[/U]. [/B]Importantly, the American Urological Association currently [URL='https://c212.net/c/link/?t=0&l=en&o=4062862-1&h=1806729242&u=https%3A%2F%2Fwww.auanet.org%2Fguidelines-and-quality%2Fguidelines%2Ftestosterone-deficiency-guideline&a=recommends']recommends[/URL] that physicians prescribing TRT inform their patients of the risks of the therapy on fertility. [B]"We are eager to begin this new pilot study, as finding an option of TRT that does not reduce fertility in men would be a significant milestone in the field of andrology and society as a whole," [/B]said Andrew Sun, M.D., Director at the Center for Men's Health at Urology Partners of North Texas and Chief Medical Advisor for Marius Pharmaceuticals. [B]"Too many men are suffering in silence from the effects of testosterone deficiency, and the results from this study could help us better understand the effects of oral TRT on spermatogenesis, which might potentially benefit a subset of men; those who are looking to start a family while still treating their low T." Led by principal investigator [URL='https://c212.net/c/link/?t=0&l=en&o=4062862-1&h=510963481&u=https%3A%2F%2Fwww.bcm.edu%2Fpeople-search%2Fmohit-khera-24469&a=Dr.+Mohit+Khera']Dr. Mohit Khera[/URL], Director of the Laboratory for Andrology Research Baylor College of Medicine, the study will enroll 20 male patients, ages 18-49 years old, who meet the American Urological Association's [URL='https://c212.net/c/link/?t=0&l=en&o=4062862-1&h=1433572264&u=https%3A%2F%2Fwww.auanet.org%2Fguidelines-and-quality%2Fguidelines%2Ftestosterone-deficiency-guideline&a=criteria']criteria[/URL] for hypogonadism and who have not previously used TRT. [/B]"Historically, testosterone products have been known to impair sperm production. Thus, many young hypogonadal men planning to achieve a pregnancy are unable to use testosterone due to an increased risk of suppressing their sperm production," said Dr. Khera. [B]"Identifying testosterone therapy that could potentially not suppress sperm production would be a significant advancement in the way we treat these hypogonadal men."[/B][/I] [B][I]Participating patients will receive 200-400mg of KYZATREX BID for three months. [U]Two semen analyses will be performed at baseline, one month, and three months, to assess any changes in each patient's sperm count[/U]. [U]Blood draws will also be taken at each of these time points to measure testosterone, hormones, lipids, and hematocrit[/U]. [U]There will also be an additional blood draw two weeks after starting the therapy to support drug titration to reach therapeutic levels[/U]. [U]Additionally, patients will receive the IIEF, PHQ-9, and SF36 questionnaires at baseline and at the conclusion of the study to assess symptoms of low testosterone[/U].[/I][/B] [I][B]This pilot study is part of Marius Pharmaceuticals' comprehensive effort to develop innovative therapies for testosterone deficiency.[/B] To learn more about KYZATREX, visit [URL='https://c212.net/c/link/?t=0&l=en&o=4062862-1&h=2765236701&u=https%3A%2F%2Fwww.kyzatrex.com%2F&a=https%3A%2F%2Fwww.kyzatrex.com']https://www.kyzatrex.com[/URL]. To learn more about Marius Pharmaceuticals, visit [URL='https://c212.net/c/link/?t=0&l=en&o=4062862-1&h=785214352&u=https%3A%2F%2Fwww.mariuspharma.com%2F&a=https%3A%2F%2Fwww.mariuspharma.com']https://www.mariuspharma.com[/URL].[/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Pilot Study Exploring the Effect of Its Oral T Therapy, KYZATREX®on Male Fertility
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top